Pharmaceutical behemoths New York-based Pfizer and London-based AstraZeneca are waging a trans-Atlantic battle over a potential multibillion-dollar buyout that has put both companies and their respective governments on the defensive.
The kerfuffle raises questions about the future of 3,100 scientists and manufacturers employed in the Maryland offices of MedImmune, a biotechnology company that local officials worry could be gutted if its corporate parent, AstraZeneca, gets bought.
{iframe}http://www.washingtonpost.com/business/capitalbusiness/medimmunes-increasing-importance-to-parent-company-may-help-if-astrazeneca-is-acquired/2014/05/18/a5e78f9e-db88-11e3-bda1-9b46b2066796_story.html{/iframe}